Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - EU Market Recap: FTSE 100 +0.10% to 9452.77, DAX (0.62%) to 24236.94, CAC40 (0.18%) to 7919.62, STOXX 600 (0.37%) to 564.54

Oct 14 ,2025

  • Synopsis:

    • European equity markets ended lower, with Spain and Finland +0.2%, joining the FTSE 100 among the leading outperformers, while Greece (1.5%), Denmark (1.0%) and Italy (0.9%) led the underperformers.

    • In political developments, in France, PM Lecornu announced suspension of France's 2023 pension reform to secure political survival. Move freezes retirement age increases until Jan-2028, meeting Socialist demands essential for government's survival. Recall also Lecornu renounced Article 49.3 only weeks ago. Two censure motions face Thursday's vote: one from La France Insoumise, the Greens, and Communists, and another from far-right Rassemblement National. All eyes rest on divided Socialists, which may submit independent no-confidence vote despite lack of internal cohesion as a third favor censure, a third oppose, and a third remain undecided(Reuters).

    • From a macroeconomic calendar perspective, UK labor market data showed increase in unemployment but wage growth continues to hold up. Final German CPI unchanged from flash. Meanwhile, latest German ZEW indicator recorded 39.3 reading in October versus consensus 40.5 and prior 37.3. but the assessment of the current situation remains very weak at -80.0 versus -75.0 forecast and prior -76.4. ZEW highlighted uncertainty related to implementation of the government's investment program and global headwinds. However, after a recent slump in exports to China, it pointed out that expectations for export-intensive sectors improved significantly in October. In terms of the broader Eurozone indicator, expectations deteriorated slightly to 22.7 versus prior 26.1 and the current situation reading at -31.8 versus -28.8, which was pinned on French political developments.

    • In corporate news, Michelin (ML.FP) cut its FY25 outlook and Publicis Groupe (PUB.FP) reported Q3 revenues. In Switzerland, Givaudan (GIVN.SW) posted strong Q3 sales and Bossard Holding (BOSN.SW) also released Q3 numbers. Out of the Nordics, LM Ericsson (ERIC.B.SS) Q3 adj EBITA reached SEK 15.80B, well above the consensus of SEK 9.16B, aided by a SEK 7.6B capital gain from selling iconectiv. Kesko (KESKOB.FH) and Alma Media (ALMA.FH) also updated investors with their most recent trading updates.

    • In the UK, BP (BP.LN) released its Q3 trading update and updated its Q3 guidance, with upstream production in Q3 now expected to be higher compared to the prior quarter. Mitie Group (MTO.LN) issued H1 Trading Update: revenue £2.7B vs year-ago £2.4B, +6.1% organic growth and announced new £100M share buyback program. Close Brothers Group (CBG.LN) increased its total provision to ~£300M in relation to proposed industry-wide redress scheme in respect of motor finance commissions. On M&A front, local Italian press wrote that MSC (Mediterranean Shipping) is assessing options for a potential takeover of EasyJet (EZJ.LN).

  • Digest:

    • Sectors - STOXX Europe 600:

      • Outperformers

        • Telecom +1.77%, Insurance +0.95%, Real Estate+0.62%, Utilities +0.50%, Construct & Mtls +0.38%, Banks +0.06%, Travel & Leisure (0.04%), Retail (0.19%), Technology (0.35%)

      • Underperformers

        • Autos & Parts (2.48%), Basic Resources (1.62%), Oil & Gas (1.00%), Health Care (0.95%), Financial Svcs (0.92%), Ind Goods & Svcs (0.91%), Chemicals (0.78%), Media (0.76%), Food & Beverage (0.43%), Persnl & HHold Goods (0.40%)

    • Macro/Peripheral markets:

      • Geopolitics

        • Trump to host Zelenskyy, signals Ukraine support (Politico)

        • Trump pushes Tomahawks for Ukraine peace (DailyMail)

        • Europe cautious on Israel despite Trump's peace deal (Politico)

      • EU

        • ESM raises €1 billion with tap of 2035 bond, completes annual funding (release )

      • UK

        • Brexit, Truss hurt UK economy, says BOE's Mann (Bloomberg)

        • UK unemployment up to 4.8% in quarter to Aug (ONS)

        • UK retail sales slow amid budget fears (Guardian)

        • UK revises planning bill to boost growth (Reuters, FT)

      • Germany

        • German inflation confirmed at 2.4% in Sep (DeStatis)

        • Germany offers tax-free pension work (FT)

      • France

        • France plans €31 billion budget squeeze (Reuters)

        • French PM to freeze retirement reform in bid to save government (Politico )

      • Spain

    • Company news:

      • Notable Gainers

        • +18.0% ERIC.B.SS (Telefonaktiebolaget LM Ericsson SEK91.94, +14.04) -- Q3 earnings; company and Vodafone announce major five-year programmable networks partnership

        • +14.1% MTO.LN (Mitie Group £1.59, +0.20) -- H1 trading update

        • +12.6% AB.FP (AB Science €1.46, +0.16) -- to hold a virtual conference on 16-Oct to provide an update on the Phase 1 study with AB8939

        • +11.5% RWA.LN (Robert Walters £1.31, +0.14) -- Q3 trading update

        • +8.8% BOWL.LN (Hollywood Bowl Group £2.86, +0.23) -- FY trading update; Peel Hunt upgrade

        • +8.5% G4M.LN (Gear4music (Holdings) £3.06, +0.24) -- H1 trading update

        • +8.0% EZJ.LN (EasyJet £5.01, +0.37) -- MSC [Mediterranean Shipping CO] Ltd assessing options for a potential EasyJet takeover -- Corriere della Sera

        • +7.9% IPH.FP (Innate Pharma €1.81, +0.13)

        • +7.0% ALMA.FH (Alma Media €15.30, +1.00) -- raises FY guidamce

        • +6.0% BOSN.SW (Bossard Holding CHF180.20, +10.20) -- Q3 revenue

        • +5.9% TOM2.NA (TomTom €5.72, +0.32) -- Q3 earnings

        • +5.3% BWY.LN (Bellway £26.10, +1.32) -- FY earnings

        • +4.8% OBD.LN (Oxford BioDynamics £0.01, -0.00) -- EpiSwitch PSE blood test named in Prostate Cancer Research NHS screening report "Prostate Cancer Screening: The Impact on the NHS"

        • +4.0% NOKIA.FH (Nokia €4.67, +0.18)

        • +3.2% FEVR.LN (Fevertree Drinks £8.12, +0.25) -- Jefferies upgrade

        • +2.5% KESKOB.FH (Kesko €18.56, +0.46) -- Sep sales

        • +2.0% ALZCUR.SS (AlzeCure Pharma SEK2.54, +0.05) -- ssues response letter to previous article published about Alzstatin's unique mode of action against Alzheimer's

        • +1.7% CBG.LN (Close Brothers Group £4.54, +0.07) -- increases total provision to ~ £300M in relation to proposed industry-wide redress scheme in respect of motor finance commissions

        • +1.6% ANOD.B.SS (Addnode Group SEK111.80, +1.80) -- Handelsbanken upgrade

      • Notable Decliners

        • -13.8% BEKB.BB (Bekaert €33.30, -5.35) -- Oddo downgrade

        • -13.2% VIS.SM (Viscofan €51.10, -7.80) -- Viscofan denies allegations of environmental and safety violations at its U.S. plant

        • -8.9% ML.FP (Cie Generale des Etablissements Michelin SA €26.11, -2.56) -- cuts FY25 outlook; Oddo downgrade

        • -6.6% MGAM.LN (Morgan Advanced Materials £2.04, -0.15) -- Q3 trading update

        • -6.4% TBCG.LN (TBC Bank Group £42.20, -2.90)

        • -5.2% NSKOG.NO (Norske Skog NOK16.80, -0.92) -- identifies several cost-reducing opportunities

        • -4.9% OXB.LN (OXB £6.15, -0.32)

        • -4.8% STLAM.IM (Stellantis €8.37, -0.42) -- Stellantis may postpone its CMD originally planned in early 2026 to mid-year -- Milano Finanza

        • -4.3% CON.GR (Continental €54.26, -2.44) -- Michelin sympathy

        • -4.1% GXI.GR (Gerresheimer €27.50, -1.18) -- UBS downgrade

        • -3.9% ONCO.SS (Oncopeptides SEK5.19, -0.21) -- issues warrants to fulfil obligations under loan agreement with EIB

        • -3.9% FAN.LN (Volution Group £6.58, -0.27) -- Peel Hunt downgrade

        • -3.8% LRE.LN (Lancashire Holdings £6.57, -0.26) -- assumed underperform at RBC Capital Markets

        • -3.5% NOVO.B.DC (Novo Nordisk DKK360.65, -12.90) -- Sumitomo Pharma and company sign co-promotion agreement for Wegovy Subcutaneous Injection in Japan

        • -3.1% SIE.GR (Siemens AG €238.35, -7.75) -- Morgan Stanley upgrade

        • -2.8% SOP.FP (Sopra Steria Group €133.50, -3.90) -- BNP Paribas Exane downgrade

        • -2.3% DIM.FP (Sartorius Stedim Biotech €182.85, -4.25)

        • -2.2% RCH.LN (Reach £0.63, -0.01) -- Q3 trading update

        • -2.1% SF.SS (Stillfront Group SEK5.41, -0.11) -- prelim Q3 earnings

        • -2.0% SZU.GR (Suedzucker €9.62, -0.20) -- expects significant improvement in Q3 EBITDA and operating profit y/y

        • -1.8% PRX.NA (Prosus €58.77, -1.06)

        • -1.6% WAWI.NO (Wallenius Wilhelmsen NOK78.65, -1.25) -- Pareto downgrade

        • -1.6% TKA.GR (ThyssenKrupp €12.68, -0.21) -- announces planned date for the initial listing of its marine business

        • -1.2% PIRC.IM (Pirelli & C. €5.86, -0.07) -- Michelin sympathy

    • EU companies reporting tomorrow:

      • Earnings:

        • Nordics: Dustin Group (DUST.SS), Diamyd Medical (DMYD.B.SS)

        • UK: Netcall (NET.LN)

  • Data:

    • Economics:

      • Finland Sep CPI +0.5% y/y vs consensus +0.6% and prior +0.5%

      • Germany Sep Final CPI +2.4% y/y vs preliminary +2.4%

      • UK Sep Claimant Count Change +25.8K vs consensus +12.0K and prior revised (2.0K) from +17.4K

      • Switzerland Sep PPI (1.8%) y/y vs consensus (2.0%) and prior (1.8%)

    • Markets:

      • WTI Crude (Nov 25): ($1.46) or (2.45%) to $58.03

      • €-$ +0.0023 or +0.20% to 1.1593

      • £-$ (0.0036) or (0.27%) to 1.3297

      • €-£ +0.0040 to 0.8719

      • S&P 500 (0.27%)

        • Performance year-to-date

        • FTSE 100: +15.66%

        • DAX: +21.74%

        • CAC: +7.30%

        • MIB: +23.08%

        • Stoxx 600: +11.21%

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE